Bluejay Diagnostics (BJDX) Stock Analysis: AI Score & Alternative Data
BJDX alt-data: headcount climbing, web traffic lagging
Is Bluejay Diagnostics a buy right now? The alternative data says hold. This BJDX stock analysis is built on the 25+ alternative data signals AltIndex tracks on Bluejay Diagnostics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 44/100: a Hold. The stock trades at $0.99 with a $1M market cap.
The bullish side of the 90-day ledger: headcount (according to LinkedIn) up 18.2% to 13 employees, and sentiment up 675.0% to 93/100. The drag: web traffic down 11.0% to 1K monthly visits. That tension is what keeps the score mid-range.
Every signal links to its own page with full history, the BJDX technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on BJDX is just below.
Bluejay Diagnostics AI Stock Analysis
Bluejay Diagnostics is an emerging medical diagnostics company specializing in the development and marketing of rapid and accurate diagnostic tests. These tests aim to enhance the quality of patient care by providing fast and reliable results.
Analysis generated August 2, 2026.
Recent Bluejay Diagnostics Stock Alerts
|
Bluejay Diagnostics | August 17 Price is down by -6.7% in the last 24h. |
|
Bluejay Diagnostics | August 11 Price is up by 6.4% in the last 24h. |
|
Bluejay Diagnostics | August 10 Price is down by -9% in the last 24h. |
|
Bluejay Diagnostics | August 7 Price is down by -6.1% in the last 24h. |
Bluejay Diagnostics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 1K | 11.0% | |
| LinkedIn Employees | 13 | 18.2% | |
| Employee Recommend | 0 | N/A | |
| Business Outlook | 0 | N/A | |
| Sentiment | 93 | 675.0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | N/A | |
| Stocktwits Mentions | 35 | 288.9% | |
| News Mentions | 0 | 100.0% | |
| Stocktwits Subscribers | 6K | 9.0% |
About Bluejay Diagnostics (BJDX)
Bluejay Diagnostics Inc. is a leading medical technology company dedicated to transforming patient care through pioneering diagnostic solutions that prioritize early disease detection. Utilizing a proprietary platform that integrates artificial intelligence with point-of-care testing, Bluejay significantly enhances the accuracy and speed of diagnostics, delivering timely and actionable insights to healthcare professionals. With a strong focus on research and development, the company is strategically positioned to address critical healthcare gaps and meet the increasing demand for innovative and reliable diagnostic tools in an evolving medical environment.
| Price | $0.99 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $1M |
| Year Range | $1 – $14 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Medical Devices |
Latest Bluejay Diagnostics News
View more →
Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation StudyJuly 21 - GlobeNewswire |
|
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq RulesJune 5 - GlobeNewswire |
|
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq RulesJune 2 - GlobeNewswire |
|
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic PartnershipJune 2 - GlobeNewswire |
|
Bluejay Diagnostics Provides First Quarter 2026 Corporate UpdateMay 7 - GlobeNewswire |
Bluejay Diagnostics Earnings & Financial Performance
View all earnings →Bluejay Diagnostics Insider Trading Activity
View all →| HRT FINANCIAL LP filed to sell 92,055 shares at $0.0. Jul 10 '26 |
| HRT FINANCIAL LP filed to sell 126,993 shares at $0.0. Jul 9 '26 |
| Dey Svetlana filed to sell 12,501 shares at $0.0. Mar 14 '26 |
| ZEIDMAN FRED S filed to sell 12,500 shares at $0.0. Mar 14 '26 |
| CHASE DONALD R filed to sell 12,525 shares at $0.0. Mar 14 '26 |
Bluejay Diagnostics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Bluejay Diagnostics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Catheter PrecisionVTAK |
$0.23 18.4% | $1M | 51 |
 |
LogicMarkLGMK |
$0.84 5.4% | — | 33 |
 |
Venus ConceptVERO |
$0.31 2.6% | — | 53 |
 |
ProfusaPFSA |
$4.34 20.6% | — | 40 |
 |
NuwellisNUWE |
$1.25 5.0% | — | 40 |
Explore Bluejay Diagnostics Data
Frequently Asked Questions: Bluejay Diagnostics (BJDX)
Bluejay Diagnostics has an AltIndex AI Score of 44/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
44/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Bluejay Diagnostics (BJDX) stock is $0.99 with a market cap of $1M.
As of today, Bluejay Diagnostics’s PE (Price to Earnings) ratio is —.
View the latest Bluejay Diagnostics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Bluejay Diagnostics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The BJDX stock price chart above shows Bluejay Diagnostics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Bluejay Diagnostics technical analysis for RSI, moving averages, and more.
See the stocks similar to Bluejay Diagnostics section on this page for companies in the same industry ranked by market cap and AI Score.
